摘要
目的比较患者昏迷与苏醒时脑脊液S100B蛋白水平,探讨脑脊液S100B蛋白指导治疗昏迷患者的临床意义及入院时GCS评分与脑脊液S100B蛋白变化之间的相关性。方法用双抗体夹心ELISA检测17例患者昏迷初期与苏醒时脑脊液S100B蛋白水平。结果 17例患者苏醒时脑脊液中S100B蛋白水平显著降低(t=3.735,P=0.002),昏迷初期脑脊液S100B蛋白含量与GOS之间有显著的负相关关系(r=-0.64,P=0.006),与入院时GCS之间有显著的负相关关系(P=0.002,r=-0.689)。57例患者入院时GCS与GOS存在显著的正相关关系(rp=0.416,P=0.001)。结论脑脊液S100B蛋白检测可早期有效评估脑损伤程度,指导昏迷患者的临床治疗及评估昏迷患者的预后。
Objective To compare cerebrospinal fluid （CSF） protein S100B levels in patients with coma and palinesthesia,to investigate the clinical significance of CSF protein S100B in treating comatose patients and the relationship between （Glasgow-coma scores）GCS and CSF protein S100B. Methods CSF protein S100B levels were determined from samples when these 17 patients in coma and palinesthesia by using double-antibody sandwich enzyme-linked immunosorbent assay（ELISA）. Results The concentrations of the CSF protein S100B decreased significantly in the 17 patients when they came around （t= 3.735,P=0.002）.And there was significantly negative relationship between GOS and the S100B concentrations in CSF when the patients in early coma （r=-0.64, P=0.006）,and there was significantly negative relationship between the initial GCS and the S100B concentrations in CSF when the patients in early coma （P=0.002,r=-0.689）.There was significantly positive relationship between the initial GCS and the GOS （rp=0.416,P=0.001）. Conclusion The S100B protein concentrations in CSF may be an effective marker to reflect the degree of the brain damage,can be used to guide the clinical treatment and to forecast the prognosis of the comatose patients.
出处
《中国现代医药杂志》
2010年第6期15-17,共3页
Modern Medicine Journal of China
